

# The Tetracyclines

## Contributors

R. K. Blackwood · J. H. Boothe · I. Chopra · B. A. Cunha  
J. J. Goodman · R. H. Gustafson · J. J. Hlavka · Z. Hošťálek  
J. S. Kiser · W. Rogalski · Z. Vaněk

## Editors

J. J. Hlavka and J. H. Boothe

# The Tetracyclines

## Contributors

R. K. Blackwood · J. H. Boothe · I. Chopra · B. A. Cunha  
J. J. Goodman · R. H. Gustafson · J. J. Hlavka · Z. Hošťálek  
J. S. Kiser · W. Rogalski · Z. Vaněk

## Editors

J. J. Hlavka and J. H. Boothe



Springer-Verlag Berlin Heidelberg New York Tokyo

**J. J. HLAVKA**  
American Cyanamid Company,  
Medical Research Division, Lederle Laboratories,  
Pearl River, NY 10987, USA

**J. H. BOOTHE**  
418 E. Longport, P.O. Box 1004,  
Ocean Gate, NJ 08740, USA

**With 77 Figures**

**ISBN 3-540-15259-8 Springer-Verlag Berlin Heidelberg New York Tokyo**  
**ISBN 0-387-15259-8 Springer-Verlag New York Heidelberg Berlin Tokyo**

Library of Congress Cataloging in Publication Data. Main entry under title: The Tetracyclines. (Handbook of experimental pharmacology; vol. 78) Includes index. 1. Tetracyclines. I. Blackwood, R. K. II. Hlavka, J. J. (Joseph J.), 1927- . III. Boothe, J. H. (James H.), 1916- . IV. Series: Handbook of experimental pharmacology; v. 78). QP905.H3 vol. 78 615'.1 s [615'.329] 85-2793 [R568-m3]  
ISBN 0-387-15259-8 (U.S.)

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law, where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1985  
Printed in Germany

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

**Product Liability:** The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting, printing and bookbinding: Brühlische Universitätsdruckerei, Giessen  
2122/3130-543210

# Handbook of Experimental Pharmacology

Continuation of Handbuch der experimentellen Pharmakologie

## Vol. 78

### *Editorial Board*

G. V. R. Born, London · A. Farah, Rensselaer, New York  
H. Herken, Berlin · A. D. Welch, Bethesda, Maryland

### *Advisory Board*

S. Ebashi · E. G. Erdös · V. Erspamer · W. S. Feldberg  
G. B. Koelle · J. R. Vane · P. G. Waser



## List of Contributors

- R. K. BLACKWOOD, Medical Research Laboratories, Central Research,  
Pfizer Inc., Groton, CT 06340, USA
- J. H. BOOTHE, 418 E. Longport, P.O. Box 1004, Ocean Gate, NJ 08740, USA
- I. CHOPRA, Department of Microbiology, University of Bristol, The Medical  
School, University Walk, Bristol BS8 1TD, Great Britain
- B. A. CUNHA, Chief, Infectious Disease Division, Department of Medicine,  
Nassau Hospital, 259 First Street, Mineola, NY 11501, USA
- J. J. GOODMAN, Medical Research Division, American Cyanamid Company,  
Lederle Laboratories, Pearl River, NY 10965, USA
- R. H. GUSTAFSON, American Cyanamid Company, Agricultural Research  
Division, P.O. Box 400, Princeton, NJ 08540, USA
- J. J. HLAVKA, American Cyanamid Company, Medical Research Division,  
Lederle Laboratories, Pearl River, NY 10987, USA
- Z. HOŠTÁLEK, Czechoslovak Academy of Sciences, Institute of Microbiology,  
Videňská 1083, CS-14220 Praha 4-Krč
- J. S. KISER, 930 North Florida Ave, De Land, FL 32720, USA
- W. ROGALSKI, E. Merck, Pharmaceutical Research, Frankfurter Str. 250,  
D-6100 Darmstadt 1
- Z. D. VANĚK, Czechoslovak Academy of Sciences, Institute of Microbiology,  
Videňská 1083, CS-14220 Praha 4-Krč

## Preface

The history of antibiotics may well have begun with the ancient Sudanese-Nubian civilization (see Chapter 1, "Historical Introduction"), but this volume reflects a more contemporary appraisal of the antibiotic era. We have compiled a comprehensive review of the tetracyclines which includes all the major subdivisions of these chemically important and clinically useful antibiotics.

There can be little doubt about the contribution of antibiotics to both the increase in human life span and the alleviation of much human suffering. The tetracyclines are still playing an important role in these areas and will continue to do so in the foreseeable future.

We hope this volume will be an important contribution to a better understanding of the chemistry, biochemistry, and medical aspects of tetracycline antibiotics.

We are indebted to the individual authors who have given so much of their time and effort in the preparation of the chapters.

Pearl River, NY  
Ocean Gate, NJ

JOSEPH J. HLAVKA  
JAMES H. BOOTHE

# Contents

## CHAPTER 1

### Historical Introduction. J. H. BOOTHE and J. J. HLAVKA

References . . . . .	3
----------------------	---

## CHAPTER 2

### Fermentation and Mutational Development of the Tetracyclines

J. J. GOODMAN

A. Introduction . . . . .	5
B. The Producing Microorganisms . . . . .	6
I. Morphology and Ultrastructure . . . . .	6
II. Mutation and Strain Selection . . . . .	8
III. Cosynthesis . . . . .	13
C. The Fermentation Process . . . . .	14
I. Inoculum . . . . .	14
II. Contamination . . . . .	16
III. Complex Media . . . . .	18
IV. Synthetic Media . . . . .	27
V. Stimulators and Inhibitors . . . . .	30
VI. Directed Fermentations . . . . .	32
D. Fermentation Technology . . . . .	38
I. Aeration . . . . .	38
II. Temperature . . . . .	40
E. Concluding Remarks . . . . .	40
References . . . . .	41

## CHAPTER 3

### Structure Determination and Total Synthesis of the Tetracyclines

R. K. BLACKWOOD. With 1 Figure

A. Introduction . . . . .	59
B. Structure Determination . . . . .	60
I. Oxytetracycline . . . . .	61
II. Chlortetracycline . . . . .	69
III. Tetracycline . . . . .	76
IV. 6-Demethyltetracyclines . . . . .	76

V. 2-Acetyl-2-decarboxamidotetracyclines . . . . .	78
VI. 6-Methylenetetracyclines . . . . .	79
VII. 6-Deoxytetracyclines and 7- and 9-Substituted 6-Deoxytetracyclines . . . . .	80
VIII. Oxytetracycline Esters . . . . .	83
IX. Tetracycline Metal Chelates . . . . .	86
C. Partial Synthesis from Derivatives . . . . .	88
I. 4-Epitetracyclines . . . . .	88
II. 12a-Deoxytetracyclines . . . . .	89
III. 5a,6-Anhydrotetracyclines and 5a(11a)-Dehydrotetracyclines . . . . .	90
IV. 4-Oxotetracyclines-4,6-hemiketals and Tetracycloxides . . . . .	91
D. Total Synthesis of Tetracycline Derivatives and Incomplete Syntheses . . . . .	92
I. Aromatic A-Ring Compounds . . . . .	92
II. Analogues Lacking the Dimethylamino Group or Other Key Functionality . . . . .	101
E. Total Synthesis of 6-Demethyl-6-deoxytetracycline . . . . .	109
I. Woodward; Conover et al. . . . .	109
II. Muxfeldt et al. . . . .	112
F. Total Synthesis of Fermentation Tetracyclines . . . . .	113
I. Tetracycline: Shemyakin et al. . . . .	113
II. Chlortetracyclines: Muxfeldt et al. . . . .	116
III. Oxytetracycline: Muxfeldt et al. . . . .	118
G. Total Synthesis of Tetracycline Analogues . . . . .	121
I. <i>dl</i> -7-Chloro-6-deoxytetracyclines . . . . .	121
II. <i>dl</i> -8-Hydroxy-6-demethyl-6-deoxytetracycline . . . . .	122
III. <i>dl</i> -6-Thiatetracycline . . . . .	124
References . . . . .	125

## CHAPTER 4

### Biosynthesis of the Tetracyclines. Z. HOŠTÁLEK and Z. VANĚK With 3 Figures

A. Introduction . . . . .	137
B. Production Strains . . . . .	137
I. Taxonomy . . . . .	137
II. Growth . . . . .	138
III. Genetics . . . . .	138
C. Building Units of Tetracyclines . . . . .	139
D. The Biosynthetic Pathway of Tetracyclines . . . . .	140
I. The Origin of the Tricyclic Nonaketide . . . . .	141
II. Transformations of the Tricyclic Nonaketide . . . . .	151
III. Transformation of the Tricyclic Decaketide . . . . .	158
IV. Genetic Loci Responsible for the Biosynthesis of Tetracyclines . . . . .	159
E. Regulation of the Biosynthesis of Tetracyclines . . . . .	159
E. Regulation of the Biosynthesis of Tetracyclines . . . . .	159
I. Saccharide Metabolism . . . . .	159
II. Formation of Malonyl CoA . . . . .	161



III. Energy Metabolism . . . . .	162
F. Biosynthesis of Macromolecules and the Production of Tetracyclines . . . . .	164
I. Nucleic Acid Metabolism . . . . .	164
II. Interaction of Tetracycline Antibiotics with Ribosomes . . . . .	165
III. Protein Synthesis . . . . .	166
IV. High-Phosphorylated Nucleotides . . . . .	168
G. Conclusion . . . . .	168
References . . . . .	169

## CHAPTER 5

**Chemical Modification of the Tetracyclines. W. POGALSKI**

With 46 Figures

A. Introduction . . . . .	179
B. Semisynthetic Tetracyclines . . . . .	181
I. Modifications at the C1 and C3 Positions . . . . .	181
II. Modifications at the C2 Position . . . . .	182
III. Modifications at the C4 Position . . . . .	190
IV. Modifications at the C5 Position . . . . .	198
V. Modifications at the C5a Position . . . . .	200
VI. Modifications at the C6 Position . . . . .	205
VII. Modifications at the C7 and C9 Positions . . . . .	214
VIII. Modifications at the C11 and C12 Positions . . . . .	223
IX. Modifications at the C11a Position . . . . .	224
X. Modifications at the C12a Position . . . . .	225
XI. Structure-Activity Relationships . . . . .	226
C. Totally Synthetic Unnatural Tetracyclines . . . . .	238
I. General Synthetic Pathways . . . . .	239
II. Anhydrotetracyclines . . . . .	243
III. ( $\pm$ ) B-Nortetracyclines . . . . .	247
IV. Modification at the C2 Position: ( $\pm$ )-4-Amino-7-chloro-2-N-methylcarbonyl-2-decarbonyl-4-dedimethylamino-6-demethyl-6-deoxytetracyclines . . . . .	249
V. Modifications at the C5a and C6 Positions: ( $\pm$ )-7-Chloro-6-deoxytetracyclines and ( $\pm$ )-7-Chloro-6-demethyl-6-deoxytetracyclines . . . . .	250
VI. Modification at the C7 Position: ( $\pm$ )-7-Methoxy-6-demethyl-6-deoxytetracyclines . . . . .	251
VII. Modification at the C8 Position: ( $\pm$ )-8-Hydroxy-6-demethoxy-6-deoxytetracyclines . . . . .	254
VIII. Modifications at the C5a Position: ( $\pm$ )-5a-Methyl-6-demethyl-6-deoxytetracyclines . . . . .	258
IX. Modifications at the C6 Position: 6-Heterotetracyclines . . . . .	266
D. Overall Structure-Activity Relationships . . . . .	298
I. Structural Requirements for Activity . . . . .	299
II. Structural Features Essential for Activity . . . . .	299
III. Effect of Structural Variation on Pharmacokinetics . . . . .	302

IV. Summary . . . . .	304
V. Conclusions . . . . .	307
References . . . . .	309

## CHAPTER 6

### Mode of Action of the Tetracyclines and the Nature of Bacterial Resistance to Them

#### I. CHOPRA. With 27 Figures

A. Introduction . . . . .	317
B. Mode of Action of the Tetracyclines: Studies Before 1964 . . . . .	318
I. Introduction . . . . .	318
II. Early Studies (1948–1953) on the Mode of Action of Tetracyclines . . . . .	318
III. Studies (1953–1964) Identifying Protein Synthesis as the Primary Target for the Action of Tetracyclines . . . . .	318
C. Current Views on the Nature of Bacterial Protein Synthesis . . . . .	319
I. Introduction . . . . .	319
II. Structure of Ribosomes . . . . .	320
III. Initiation of Protein Synthesis . . . . .	321
IV. Recognition of Internal Codons . . . . .	323
V. Peptide Bond Formation and Translocation . . . . .	323
VI. Termination of Protein Synthesis . . . . .	324
D. Effects of Tetracyclines on Protein Synthesis in Prokaryotes . . . . .	324
I. Effects of Tetracyclines on the Synthesis of Protein In Vivo . . . . .	324
II. Effects of Tetracyclines on the Synthesis of Protein In Vitro . . . . .	325
E. Binding of Tetracyclines to Macromolecules . . . . .	329
I. Introduction . . . . .	329
II. Binding of Tetracyclines to Ribosomes . . . . .	330
F. Molecular Basis of Tetracycline Action . . . . .	331
G. Relation Between Structure and Activity in the Tetracyclines . . . . .	332
H. Effects of Growth in the Presence of Low Tetracycline Concentrations on Microbial Metabolism . . . . .	334
I. Selective Toxicity of the Tetracyclines . . . . .	334
I. Introduction . . . . .	334
II. Entry of Tetracyclines into Eukaryotic Cells . . . . .	335
III. Effect of Tetracyclines on Eukaryotic Protein Synthesis . . . . .	335
IV. Selective Toxicity of the Tetracyclines – The Apparent Paradox Explained . . . . .	335
J. Transport of Tetracyclines into Bacteria . . . . .	336
I. Introduction . . . . .	336
II. Transport of Tetracyclines Across the Gram-Negative Outer Membrane . . . . .	337
III. Transport of Tetracyclines Across the Cytoplasmic Membrane of Gram-Positive and-Negative Bacteria . . . . .	339
IV. Fluorescence Assay for Tetracycline Transport – A Cautionary Tale . . . . .	342
V. Transport of Tetracycline Across the Bacterial Cytoplasmic Membrane: Conclusion . . . . .	343

K. Plasmid-Determined Resistance to the Tetracyclines . . . . .	344
I. Occurrence of Plasmids in Natural Bacterial Isolates . . . . .	344
II. Tetracycline-Resistance Determinants: Transposable and Amplifiable Sequences . . . . .	344
III. Genetic Comparison of Regions Coding for Tetracycline Resistance . . . . .	347
IV. Proteins Synthesized by Tetracycline-Resistance Determinants: General Nature of the Proteins and Organization of the Genes Which Encode Them . . . . .	348
V. Mode of Action of Membrane-Located Resistance Proteins . . . . .	356
VI. Membrane Architecture in Relation to the Binding and Function of Plasmid-Determined Tetracycline-Resistance Proteins . . . . .	359
VII. Membrane-Located Resistance Proteins: Specific Properties and Comparisons Between Proteins Encoded by Different Determinants . . . . .	359
VIII. Gene Copy Number and Decreased Tetracycline Accumulation . . . . .	362
IX. Are the Membrane-Located Resistance Proteins That Mediate Efflux the Only Products Responsible for Resistance? . . . . .	363
X. Therapeutic Consequences of Tetracycline-Resistance Gene Amplification . . . . .	365
XI. Use of the Fluorescence Assay for Tetracycline for Studies on Plasmid-Determined Resistance . . . . .	365
XII. Inducibility of Plasmid-Determined Resistance to Tetracycline . . . . .	365
XIII. Expression of Tetracycline Resistance in <i>Escherichia coli</i> Renders Cells Hypersensitive to Lipophilic Chelating Agents . . . . .	369
XIV. Epidemiology of Tetracycline Resistance . . . . .	369
XV. Origin of Plasmid-Located Tetracycline-Resistance Genes . . . . .	371
L. Chromosomal Mutation to Tetracycline Resistance . . . . .	376
M. Conclusions . . . . .	377
References . . . . .	378

## CHAPTER 7

**Clinical Uses of the Tetracyclines. B. A. CUNHA**

A. Antimicrobial Activity . . . . .	393
B. Clinical Uses . . . . .	393
C. Treatment of First Choice . . . . .	395
D. Effective Alternative Treatment . . . . .	398
E. Treatment of Clinical Syndromes . . . . .	400
F. Ineffective Treatment . . . . .	401
G. Dosage and Duration of Therapy . . . . .	402
References . . . . .	403

## CHAPTER 8

**Nonmedical Uses of the Tetracyclines. R. H. GUSTAFSON and J. S. KISER**

A. Historical . . . . .	405
-------------------------	-----

<b>B. Growth Promotion and Improved Feed Efficiency in Livestock</b> . . . . .	406
I. Poultry . . . . .	406
II. Cattle . . . . .	408
III. Horses . . . . .	409
IV. Swine . . . . .	409
<b>C. Disease Prevention Effects of Chlortetracycline and Oxytetracycline</b> . . . . .	412
I. Poultry . . . . .	412
II. Ducks . . . . .	415
III. Chickens . . . . .	415
IV. Cattle . . . . .	415
V. Sheep . . . . .	417
VI. Swine . . . . .	418
<b>D. Public Health Considerations</b> . . . . .	420
I. Epidemiology of Antibiotic Resistance . . . . .	420
II. Salmonella . . . . .	422
III. Tissue Residues . . . . .	426
<b>E. Government Restrictions</b> . . . . .	432
I. Great Britain and Europe . . . . .	432
II. United States . . . . .	435
III. Far East . . . . .	438
<b>References</b> . . . . .	439
<b>Subject Index</b> . . . . .	447

## CHAPTER 1

# Historical Introduction

J. H. BOOTHE and J. J. HLAVKA

The tetracyclines have been an important component in the treatment of bacterial infections since their discovery in 1948. During this time the literature relating to these antibiotics has become quite voluminous, complex, and scattered among publications in many different scientific disciplines and languages. Numerous reviews of specific areas have been written in the past, such as the recent comprehensive review by MITSCHER (1978), but the present work is, to our knowledge, the first attempt to combine reviews of all the major subdivisions from chemistry to clinical applications of the tetracyclines in one volume. It should be understood, however, that no review could (or should) contain every literature reference to the subject being reviewed, but rather that important and pertinent literature be selected to illustrate the various chapters.

The history of antibiotics began with the often-told events related to the observations of penicillin activity by Fleming in 1928, the rediscovery and purification by Florey and Chain in 1938, and the large-scale development and clinical use of penicillin during World War II. By 1946-1947, the problems related to penicillin production had essentially been solved. The material was readily available at a reasonable price, and in fact the world's needs could be satisfied by a few large efficient pharmaceutical producers. Stimulated by the tremendous successes of penicillin, many of the drug companies and academic institutions now began to search for new antibiotics by screening soil samples for antibiotic-producing microorganisms. Such a screening program was established at Lederle Laboratories and surprisingly quickly the producer of what became known as chlortetracycline or Aureomycin was discovered (DUGGAR 1948). In retrospect, the early discovery of the penicillin and the tetracycline families of antibiotics seems especially fortuitous since large screening programs in the succeeding 30-40 years have discovered relatively few, new and useful families of antibiotics even though about 6,000 antibiotics have now been described in the literature.

Chlortetracycline was introduced to the medical profession in 1948 and was enthusiastically accepted on the basis of its merits. It first of all inhibited a much wider spectrum of microorganisms than the then available penicillins, covering not only the gram-positive organisms but many of the gram-negative ones as well. Secondly, it was orally active, being very well absorbed from the stomach and upper small intestine. The second member of the family, oxytetracycline, was discovered independently by the Charles Pfizer Company and introduced in 1950 (FINDLAY et al. 1950). In 1953, the nomenclature parent of the series, tetracycline, was discovered (BOOTHE et al. 1953; CONOVER et al. 1953) and introduced, and rather quickly became the favorite of the medical profession. Tetracycline was



discovered almost simultaneously as a product of reductive dechlorination of chlortetracycline and as a fermentation product of a *Streptomyces* species (MINIERI et al. 1953, 1954). The study of mutant strains of *Streptomyces*, both natural and induced, undertaken in attempts to improve fermentation yields, provided the next medically useful tetracycline, 6-demethylchlortetracycline (McCORMICK et al. 1957). This compound provided clinically useful antibiotic blood levels for longer periods, thus permitting the use of lower dose levels to produce the same therapeutic effect.

The remaining medically useful members of the tetracycline family, rondomycin (BLACKWOOD et al. 1963), doxycycline (STEPHENS et al. 1963), and minocycline (MARTELL and BOOTHE 1967) were all the results of lengthy programs of chemical modification of members of the naturally occurring tetracyclines. These semisynthetic tetracyclines will be reviewed in some detail later in this book, but briefly these compounds offer improved therapeutic efficacy in the areas of potency, serum half-life, and, in some cases, broadened spectrum of activity.

Having reviewed the relatively brief, 50-year history of antibiotics in medicine, and the even shorter history of the tetracyclines, it should be noted that these compounds probably played a role in ancient history that has not yet been fully appreciated or studied. In 1980, a group of anthropologists from the University of Massachusetts observed fluorescent areas in bones obtained from an ancient (350 A.D.) Sudanese-Nubian civilization. These fluorescent areas were identical both as to location in the bone and fluorescent characteristics to modern bone from patients treated with tetracycline antibiotics (BASSETT et al. 1980). This observation has been at least partially confirmed by fluorescence spectrum measurements and by microbiological inhibition studies of the old bone (BOOTHE 1984). The deposition of tetracycline antibiotics in developing bones and teeth as a very stable calcium chelate complex was observed early in biological studies. In fact, it is the basis for the recommendation that children below the age of 8 years should not be treated with tetracyclines because of occasional teeth staining.

If we assume that at least some ancient civilizations were exposed to tetracycline antibiotics (and perhaps to other antibiotics which were less stable and thus decomposed in the intervening years) the question arises as to the source. The most likely answer seems to be that they were produced during the growth of an antibiotic-producing organism either in stored grain or in some fermented liquid such as a beer.

It may be instructive to make future determinations as to which competing civilizations were exposed to these antibiotics, for example, the Greeks or the Persians, the Romans or the Carthaginians, the Philistines or the Israelites.

The scientific and medical history of the tetracycline antibiotics seems to have been paralleled by a long and complicated series of legal entanglements. It often seemed that the legal minds were as numerous and as active as the scientific ones. Some of the more prominent of these legal affairs are briefly described: (1) In the late 1950s a number of cultures of tetracycline-producing streptomycetes, along with much technical information, were stolen from the Lederle Laboratories by a few employees and sold to some foreign producers. The solving of the case and the prosecution of the leader is described in some detail in *The Million Dollar Bugs* (PEARSON 1969), which makes a lively detective yarn. (2) Congressional hearings

on the questions of pricing and price fixing were held by various committees over a number of years beginning in 1959 with those held by the late Senator Estes Kefauver. (3) The Federal Trade Commission held hearings and proceedings at various times from 1958 to 1968 which resulted in an order to allow open licensing of tetracycline. (4) Criminal proceedings involving conspiracy to fix prices were brought in 1961 by the US Department of Justice against the five companies who made and sold tetracycline antibiotics. The companies were first convicted of price fixing, but the US Court of Appeals later reversed the conviction, and the reversal was affirmed by the US Supreme Court. The case was remanded for a new trial, and on retrial the companies were found not guilty. (5) The original conviction for price fixing stimulated the filing of civil suits by large users of tetracycline to recover overpayments. One hundred and fifty-eight treble damage actions were filed, many of which were settled before the reversal of the conviction. After the price-fixing conviction was reversed, the civil suits were based mainly on the contention that the original patent on tetracycline had been obtained fraudulently by withholding information from the patent examiner. The most recent and final judicial decision has affirmed the validity of the 1955 tetracycline patent and the last legal action against the companies was dropped in 1982.

## References

- Bassett EJ, Keith MS, Armelagos GJ, Martin DL, Villanueva AR (1980) Tetracycline labeled human bone from ancient Sudanese Nubia (A.D. 350). *Science* 209:1532
- Blackwood RK, Beereboom JJ, Rennhard HH, Schach von Wittenau M, Stephens CR (1963) 6-Methylenetetracyclines. III. Preparation and properties. *J Am Chem Soc* 85:3943
- Boothe JH, Morton J, Petisi JP, Wilkinson RG, Williams JH (1953) Tetracycline. *J Am Chem Soc* 75:4621
- Boothe JH (to be published) Tetracycline antibiotics in an ancient civilization. *Science*
- Conover LH, Moreland WT, English AR, Stephens CR, Pilgrim FJ (1953) Terramycin. XI. Tetracycline. *J Am Chem Soc* 75:4622
- Duggar BM (1948) Aureomycin. *Ann NY Acad Sci* 51:177
- Findlay AC, Hobby GL, Pan SY, Regna JB, Routien DB, Seeley DB, Shull GM, Sobin BA, Solomons IA, Vinson JW, Kane JH (1950) Terramycin, a new antibiotic. *Science* 111:85
- Martell MJ, Boothe JH (1967) The 6-deoxytetracyclines. VII. Alkylated aminotetracyclines possessing unique antibacterial activity. *J Med Chem* 10:44
- McCormick JRD, Sjolander NO, Hirsch U, Jensen ER, Doerschuk AP (1957) A new family of antibiotics: The demethyltetracyclines. *J Am Chem Soc* 79:4561
- Minieri PP, Firman MC, Mistretta AG, Abbey A, Bricker CE, Rigler NE, Sokol H (1953-1954) A new broad spectrum antibiotic product of the tetracycline group. *Antibiotics Annual. Proc Symposium Antibiotics*, Washington DC, pp 81-87
- Mitscher LA (1978) The chemistry of the tetracycline antibiotics. In: *Medicinal research*, vol 9. Dekker, New York
- Pearson M (1969) *The million dollar bugs*. Putnam, New York
- Stephens CR, Beereboom JJ, Rennhard HH, Gordon PN, Murai K, Blackwood RK, Schach von Wittenau M (1963) 6-Deoxytetracyclines. IV. Preparation C-6 stereochemistry, and reactions. *J Am Chem Soc* 85:2643

on the questions of pricing and price fixing were held by various committees over a number of years beginning in 1959 with those held by the late Senator Estes Kefauver. (3) The Federal Trade Commission held hearings and proceedings at various times from 1958 to 1968 which resulted in an order to allow open licensing of tetracycline. (4) Criminal proceedings involving conspiracy to fix prices were brought in 1961 by the US Department of Justice against the five companies who made and sold tetracycline antibiotics. The companies were first convicted of price fixing, but the US Court of Appeals later reversed the conviction, and the reversal was affirmed by the US Supreme Court. The case was remanded for a new trial, and on retrial the companies were found not guilty. (5) The original conviction for price fixing stipulated the fixing of civil suits by large users of tetracycline to recover overpayments. One hundred and fifty-eight trouble damage actions were filed, many of which were settled before the reversal of the conviction. After the price-fixing conviction was reversed, the civil suits were based mainly on the contention that the original patent on tetracycline had been obtained fraudulently by withholding information from the patent examiner. The most recent and final judicial decision has affirmed the validity of the 1955 tetracycline patent and the last legal action against the companies was dropped in 1982.

## References

1. Durrant, E.J., Keith, J.R., Armstrong, G.J., Mann, D.J., Vinnicombe, A.R. (1980) Tetracycline labeled human urine from a renal transplant patient. *J. Pharm. Med.* 209-212.
2. Blackwood, R.R., Bessborough, H., Berglund, H.H., Schach, von Wittenau, M., Stephens, G.R. (1967) 6-Methyl-tetracycline. III. Preparation and properties. *J. Am. Chem. Soc.* 89:1041-1042.
3. Boucher, J.H., Morton, J., Fend, J.B., Williamson, R.O., Williams, H. (1973) Tetracycline. I. Am. Chem. Soc. 95:452.
4. Boucher, J.H. (to be published). Tetracycline antibiotics in an ancient civilization. *Science*.
5. Conover, L.J., Martineau, W.T., Ball, A.R., Stephens, G.R., Pridgen, E.J. (1973) Tetracycline. XI. Tetracycline. *J. Am. Chem. Soc.* 95:452.
6. Durrant, E.J. (1944) *Antibiotics*. (N.Y.: Acad. Sci. 1).
7. Linder, A.C., Hober, J.L., Pao, S.Y., Rogers, R.R., Smith, D.B., Seely, D.B., Smith, D.B., Smith, D.B., Smith, D.B. (1950) Tetracycline, a new antibiotic. *Science* 111:72.
8. Marshall, M.J., Boucher, J.H. (1967) The 6-deoxy-tetracycline. V. Antibiotic and tetracycline. *Antibiotic and tetracycline activity*. *J. Med. Chem.* 10:44.
9. McCormick, J.R., Schach, von Wittenau, M., Hober, J.L., Smith, D.B. (1957) A new type of antibiotic. The demethyl-tetracycline. *J. Am. Chem. Soc.* 79:4561.
10. Munich, E.P., Fyfe, M.C., Minner, A.G., Abbey, A., Baker, G.B., Riddle, H.E. (1957) A new broad spectrum antibiotic product of the tetracycline group. *Antibiotic and tetracycline activity*. *J. Med. Chem.* 10:44.
11. Mitchell, J.A. (1972) The chemistry of the tetracycline antibiotics. In: *Medicinal research*. Vol. 9. *Interscience*. New York.
12. Fyfe, M.C. (1957) The tetracycline antibiotics. *Interscience*. New York.
13. Stephens, G.R., Bessborough, H., Berglund, H.H., Schach, von Wittenau, M., Blackwood, R.R., Schach, von Wittenau, M. (1953) 6-Methyl-tetracycline. V. Preparation of 6-methyl-tetracycline and tetracycline. *J. Am. Chem. Soc.* 75:2543.

## CHAPTER 2

# Fermentation and Mutational Development of the Tetracyclines

J.J. GOODMAN

### A. Introduction

The first of the tetracycline family of antibiotics, chlortetracycline (CTC), was introduced over 3 decades ago (DUGGAR 1948) and in the following years, with the introduction of new members of the family, the tetracyclines have retained their importance in both human therapy and animal feed use. According to reports of the US Tariff Commission, annual production is in the order of 11,000–13,000 tonnes. Numerous reviews dealing with the pathways of biosynthesis and the genetics and biochemistry of the producing organisms have appeared and these will be cited in the appropriate sections. The production aspects of the fermentation and the factors leading to higher yields have been dealt with less frequently and this is understandable in view of the proprietary nature of much of the information. An excellent review by DI MARCO and PENNELLA appeared in 1959 (DI MARCO and PENNELLA 1959) and the most recent general review is by HOSTALEK et al. (1979). A great deal of the pertinent information is to be found in the patent literature, where, again for obvious reasons, only minimal disclosures are often made. A compendium giving excerpts from the United States patent literature appeared in 1968 (EVANS 1968). This review will attempt to deal with the fermentation and mutational development of the tetracyclines from the practical perspective of increasing fermentation potencies. The large number of enzymes and individual steps involved in biosynthesis and the large number of possible compounds on the pathway to the final products (see HOSTALEK et al. 1974 for a review) can all have a potential effect on ultimate yield. As products of fermentation the tetracyclines are “mature” products. If a recent report (BASSETT et al. 1980) on their detection in ancient bones holds up, their existence predates the antibiotic era by at least 1,400 years! In the modern antibiotic era as products mature, improved production strains come along more slowly and useful media combinations are more likely already to have been tested. Maintenance of high yields becomes increasingly a matter of constant attention to small details rather than through some dramatic change. As more sophisticated production technologies get locked in place it becomes more difficult to introduce changes. The gap between tank results and shaken flask results becomes wider though one may hope that the latter will still be predictive of the potential of a new strain or medium ingredient.

This review will include both older as well as the more recent literature citations. Where no specific organism is stated all reference to oxytetracycline (OTC) production will be by *Streptomyces rimosus*, and similarly unless otherwise stated in the text references to production of any of the other tetracyclines will be by